浏览全部资源
扫码关注微信
上海中医药大学附属曙光医院传统医学科,上海 201203
硕士研究生。研究方向:中医药治疗炎症性肠病。 E-mail:zc0726@foxmail.com
主任医师,教授,博士生导师。研究方向:中医药治疗脾胃病及中医药国际标准化。E-mail:doudanbo@shutcm.edu.cn
纸质出版日期:2024-03-15,
收稿日期:2023-06-17,
修回日期:2024-01-29,
扫 描 看 全 文
曾铖,顾思臻,黄诗韵等.2013-2023年中医药治疗溃疡性结肠炎的文献计量学分析 Δ[J].中国药房,2024,35(05):548-554.
ZENG Cheng,GU Sizhen,HUANG Shiyun,et al.Traditional Chinese medicine in the treatment of ulcerative colitis in 2013-2023: a bibliometric analysis[J].ZHONGGUO YAOFANG,2024,35(05):548-554.
曾铖,顾思臻,黄诗韵等.2013-2023年中医药治疗溃疡性结肠炎的文献计量学分析 Δ[J].中国药房,2024,35(05):548-554. DOI: 10.6039/j.issn.1001-0408.2024.05.07.
ZENG Cheng,GU Sizhen,HUANG Shiyun,et al.Traditional Chinese medicine in the treatment of ulcerative colitis in 2013-2023: a bibliometric analysis[J].ZHONGGUO YAOFANG,2024,35(05):548-554. DOI: 10.6039/j.issn.1001-0408.2024.05.07.
目的
2
利用文献计量学方法分析中医药治疗溃疡性结肠炎(UC)的研究现状及热点。
方法
2
检索2013年1月至2023年4月中国知网核心期刊数据库及Web of Science核心合集数据库内中医药治疗UC的临床研究、基础研究和药理学研究等文献,利用CiteSpace 6.1.R6软件对纳入文献的作者、机构、关键词等进行文献计量学分析,并绘制可视化图谱。
结果
2
共纳入中文文献1 060篇,英文文献555篇。2013-2023年,中医药治疗UC的相关研究发文量总体呈上升趋势;纳入文献中,中文核心作者有59位,英文核心作者有33位,且形成了以多个关键学者为中心的稳定团体。中文研究热点集中在名医经验、经典名方等方面,英文研究热点集中在细胞、表达、激活、信号通路等方面。肠道菌群、炎症因子等机制方面的研究在中英文文献中均备受关注。
结论
2
近年来,中医药领域中UC的相关研究已取得一定进步。未来相关学者应在保持中医药特色的基础上加强临床研究方案的顶层设计,重视中医药治疗UC的长期疗效评价,并应积极利用代谢组学、蛋白质测序等新技术探索中药配伍治疗疾病的科学内涵。
OBJECTIVE
2
To analyze the current research status and hotspots of traditional Chinese medicine (TCM) in the treatment of ulcerative colitis (UC) via bibliometrics method.
METHODS
2
The clinical, basic, and pharmacological research of TCM in the treatment of UC in the CNKI core journals database and Web of Science core collection database were searched from January 2013 to April 2023. The CiteSpace 6.1.R6 software was adopted to analyze the number of authors, institutions and keywords. What’s more, a visual map was plotted.
RESULTS
2
Overall, 1 060 Chinese articles and 555 English articles were included. In 2013-2023, the number of relevant research documents issued by TCM in the treatment of UC has shown a significant upward trend. Among the included literature, there are 59 core authors in Chinese and 33 core authors in English. A stable group centered on multiple key scholars has been formed. Chinese research hotspots focus on the experience of famous doctors, classical famous prescriptions, etc.; English research hotspots center on cells, expression, activation,signaling pathway, etc. The study of intestinal flora, inflammatory factors, and other mechanisms has attracted much attention in both Chinese and English literature.
CONCLUSIONS
2
In recent years, some progress has been made in the study of treating UC with TCM. In the future, the top-level design of clinical research protocols based on maintaining the characteristics of TCM should be strengthened. Moreover, the long-term efficacy evaluation of TCM in the treatment of UC should be emphasized, and new technologies such as metabolomics and protein sequencing should be actively adopted to explore the scientific connotation of TCM compatibility in treating diseases.
溃疡性结肠炎中医药文献计量学可视化分析
traditional Chinese medicinebibliometricsvisual analysis
KOBAYASHI T,SIEGMUND B,LE BERRE C,et al. Ulcerative colitis[J]. Nat Rev Dis Primers,2020,6:74.
RAINE T,BONOVAS S,BURISCH J,et al. ECCO guidelines on therapeutics in ulcerative colitis:medical treatment[J]. J Crohns Colitis,2022,16(1):2-17.
BISGAARD T H,ALLIN K H,KEEFER L,et al. Depression and anxiety in inflammatory bowel disease:epidemio-logy,mechanisms and treatment[J]. Nat Rev Gastroenterol Hepatol,2022,19(11):717-726.
UNGARO R,COLOMBEL J F,LISSOOS T,et al. A treat-to-target update in ulcerative colitis:a systematic review[J]. Am J Gastroenterol,2019,114(6):874-883.
HIRTEN R P,SANDS B E. New therapeutics for ulcera-tive colitis[J]. Annu Rev Med,2021,72:199-213.
吴澎泞,熊帅,杨婉卿,等. 托法替尼治疗溃疡性结肠炎的研究进展[J]. 中国药房,2022,33(18):2299-2304.
WU P N,XIONG S,YANG W Q,et al. Research advances of tofacitinib in the treatment of ulcerative colitis[J]. China Pharm,2022,33(18):2299-2304.
陈文煦,晨迪,沈爱宗. 英夫利昔单抗治疗溃疡性结肠炎的成本-效用分析[J]. 中国药房,2020,31(22):2750-2756.
CHEN W X,CHEN D,SHEN A Z. Cost-utility analysis of infliximab in the treatment of ulcerative colitis[J]. China Pharm,2020,31(22):2750-2756.
NG S C,SHI H Y,HAMIDI N,et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st Century:a systematic review of population-based studies[J]. Lancet,2017,390(10114):2769-2778.
ZHANG X,ZHANG L,CHAN J C P,et al. Chinese herbal medicines in the treatment of ulcerative colitis:a review[J]. Chin Med,2022,17(1):43.
荣红国,于蔚洁,杜美皎,等. 我国循证中医药领域研究热点与前沿分析[J]. 中国药房,2022,33(15):1876-1880.
RONG H G,YU W J,DU M J,et al. Analysis on research hotspots and frontier in domestic evidence-based traditional Chinese medicine[J]. China Pharm,2022,33(15):1876-1880.
江学良,崔慧斐. 中国溃疡性结肠炎10 218例的特点[J]. 世界华人消化杂志,2001,9(8):869-873.
JIANG X L,CUI H F. Features of ulcerative colitis in China:an analysis 10 218 cases[J]. World Chin J Dig,2001,9(8):869-873.
张声生,沈洪,郑凯,等. 溃疡性结肠炎中医诊疗专家共识意见:2017[J]. 中华中医药杂志,2017,32(8):3585-3589.
ZHANG S S,SHEN H,ZHENG K,et al. Consensus opinion of TCM diagnosis and treatment experts on ulcerative colitis:2017[J]. China J Tradit Chin Med Pharm,2017,32(8):3585-3589.
高阳,顾思臻,陈侃俊,等. 窦丹波应用青玉散治疗溃疡性结肠炎的思考和临证体会[J]. 中华中医药杂志,2021,36(9):5311-5315.
GAO Y,GU S Z,CHEN K J,et al. Thinking and clinical experience of DOU Dan-bo in treating ulcerative colitis with Qingyu powder[J]. China J Tradit Chin Med Pharm,2021,36(9):5311-5315.
SHEN H,ZHANG S S,ZHAO W X,et al. Randomised clinical trial:efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter,randomized,and double-blind clinical trial of patients with moderately active ulcerative colitis[J].Biomedecine Pharmacother,2021,139:111580.
张亚利,郑烈,郭倩,等. 健脾清肠方对激素依赖脾虚湿热型溃疡性结肠炎患者激素撤退的影响[J]. 中国实验方剂学杂志,2020,26(4):109-113.
ZHANG Y L,ZHENG L,GUO Q,et al. Clinical efficacy of Jianpi qingchang decoction in treating patients with spleen deficiency damp-heat hormone-dependent ulcera-tive colitis[J]. Chin J Exp Tradit Med Formulae,2020,26(4):109-113.
崔松香,卢海霞,陆为民. 国医大师徐景藩从脾论治溃疡性结肠炎经验浅析[J]. 中华中医药杂志,2022,37(10):5763-5766.
CUI S X,LU H X,LU W M. TCM master XU Jingfan’s experience of treating ulcerative colitis from the spleen[J]. China J Tradit Chin Med Pharm,2022,37(10):5763-5766.
王斌,吴春晓,孙建慧,等. 基于数据挖掘的中药专利复方治疗溃疡性结肠炎的用药规律分析[J]. 中国中医基础医学杂志,2023,29(5):785-789.
WANG B,WU C X,SUN J H,et al. Analysis of drug use rules of Chinese patent compound medicine in treatment of ulcerative colitis based on data mining[J]. J Basic Chin Med,2023,29(5):785-789.
UCHIYAMA K,TAKAMI S,SUZUKI H,et al. Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis:an investigator-initiated multicenter double-blind clinical trial[J]. PLoS One,2020,15(11):e0241337.
高阳,顾思臻,薛艳,等. 基于芳香烃受体探讨青黛及其主要成分缓解溃疡性结肠炎的作用机制[J]. 中国中医药信息杂志,2023,30(11):126-131.
GAO Y,GU S Z,XUE Y,et al. Discussion on the mechanism of natural indigo and its main components in relieving ulcerative colitis based on aryl hydrocarbon receptor[J]. Chin J Inf Tradit Chin Med,2023,30(11):126-131.
HERRERA-DEGUISE C,VARELA E,SARRABAYROUSE G,et al. Gut microbiota composition in long-remission ulcerative colitis is close to a healthy gut microbiota[J]. Inflamm Bowel Dis,2023,29(9):1362-1369.
XIE J,TIAN S M,LIU J,et al. Combination therapy with indigo and indirubin for ulcerative colitis via reinforcing intestinal barrier function[J]. Oxid Med Cell Longev,2023,2023:2894695.
YANG L,LUO H,TAN D C,et al. A recent update on the use of Chinese medicine in the treatment of inflammatory bowel disease[J]. Phytomedicine,2021,92:153709.
NA Y R,STAKENBORG M,SEOK S H,et al. Macrophages in intestinal inflammation and resolution:a potential therapeutic target in IBD[J]. Nat Rev Gastroenterol Hepatol,2019,16(9):531-543.
WANG Y F,ZHANG J Q,ZHANG B H,et al. Modified Gegen qinlian decoction ameliorated ulcerative colitis by attenuating inflammation and oxidative stress and enhancing intestinal barrier function in vivo and in vitro[J]. J Ethnopharmacol,2023,313:116538.
0
浏览量
10
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构